Mitochondrial iron metabolism is significantly enhanced in cancer cells, aiding in resistance to anticancer therapy; thus, inducing mitochondrial dysfunction through IRP2 inhibition is a prospective area of research [8, 24]. Here, IREB2 is linked to cancer.